German biotech company Proteros biostructures has signed a second research agreement with Merck Sharp & Dohme in the US to develop small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.

The companies signed the initial agreement in October last year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the new agreement, Proteros will receive an upfront payment and research funding, as well as development, regulatory and commercial milestone payments of up to $167m, including tiered royalties.

Proteros biostructures CEO Dr Torsten Neuefeind said: “We are pleased to expand our relationship with MSD just one year after starting our first collaboration in epigenetic drug discovery.

“This new collaboration will benefit from our previous and ongoing work with the team at MSD and we look forward to a further successful partnership, which potentially could transform the treatment of many cancers.”

See Also:

"We are pleased to expand our relationship with MSD just one year after starting our first collaboration in epigenetic drug discovery."

Epigenetics addresses a new paradigm in the organisation of genetic information and covers a class of enzymes and various potential drug targets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Epigenetic changes provide the potential to reverse disease processes.

The nucleosomal epigenetic assay technologies (NEAT) and the structure guided discovery platform of Proteros allow the opening of gateways to address epigenetic mechanisms for new medicines.

Under the initial agreement, MSD obtained access to Proteros’ technology and structure guided discovery platform.

Proteros received up to $126m in research, development, regulatory and commercial milestone payments.